ContraFect (ContraFect) Change In Working Capital : $-9.54 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ContraFect Change In Working Capital?

ContraFect's change in working capital for the quarter that ended in Sep. 2023 was $-2.85 Mil.

ContraFect's change in working capital for the fiscal year that ended in Dec. 2022 was $13.76 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

ContraFect Change In Working Capital Historical Data

The historical data trend for ContraFect's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Change In Working Capital Chart

ContraFect Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

2.00

-1.71

-2.27

1.77

13.76

ContraFect Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Working Capital	Get a 7-Day Free Trial															11.14	-4.51	-1.03	-1.15	-2.85

ContraFect Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.54 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

ContraFect Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ContraFect's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ContraFect (ContraFect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701

Website

https://www.contrafect.com

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Executives

Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger	officer: VP Finance	238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff	director	1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low	director	EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi	director	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner	officer: SVP Business Development	30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	10 percent owner	BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd	10 percent owner	FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino	officer: Chief Medical Officer	757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos	officer: General Counsel	207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421